ERBB2 and neoplasm: [18F]FDG has also been used for labelling genetically engineered NK-92-scFv(FRP5)-zeta natural killer cells in preclinical models: Higher uptake of NK-92-scFv(FRP5)-zeta cells were seen in HER2/neu-positive tumours within a 2-h time frame compared to the parental NK-92 cells and confirmed on autoradiography and histopathology [23].